Meeting
2020 ASCO Virtual Scientific Program
Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib.
Authors
Constantine Si Lun Tam
Peter MacCallum Cancer Centre, Melbourne, St Vincent’s Hospital, Fitzroy, University of Melbourne, Parkville and Royal Melbourne Hospital, Parkville, Victoria, Australia
Constantine Si Lun Tam , Stephen Opat , Paula Marlton , David Gottlieb , David Simpson , Gavin Cull , David Ritchie , Emma Verner , Javier Munoz , Alessandra Tedeschi , Jane Huang , William Novotny , Ziwen Tan , Eric Holmgren , Siminder K. Atwal , John Francis Seymour , Andrew Warwick Roberts , Judith Trotman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02343120
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8051)
DOI
10.1200/JCO.2020.38.15_suppl.8051
Abstract #
8051
Poster Bd #
384
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Study of cabozantinib in second line under real-life setting in patients with advanced renal cell carcinoma (aRCC): Study design of a French retrospective, multicenter study (OCTOPUS).
First Author: Antoine Thiery-Vuillemin
Poster
2021 ASCO Annual Meeting
Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.
First Author: Jorge J. Castillo
Poster
2020 Gastrointestinal Cancers Symposium
Long-term safety and efficacy of lanreotide treatment in Japanese patients with neuroendocrine tumors: Final analysis of a phase II open-label extension study.
First Author: Tetsuhide Ito
Poster
2017 Gastrointestinal Cancers Symposium
The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
First Author: Eric Raymond